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 Propionic acidemia is a rare metabolic disorder caused by a deficiency of 
propionyl- CoA carboxylase, the enzyme that converts propionyl-CoA to 
methylmalonyl-CoA.  Patients with propionic acidemia cannot metabolize propionic 
acid, which sequesters oxaloacetate from the Krebs cycle to form methylcitric acid. This 
may lead to a deficiency in Krebs cycle intermediates.  Our study looked at whether 
adding glutamate, citrate, or ornithine α-ketoglutarate (chemicals that could fill up the 
Krebs cycle as anaplerotic agents) to patients’ diets affected plasma levels of glutamine 
and ammonia, and the urinary excretion of Krebs cycle intermediates.  We also looked 
at developmental markers and hospitalizations to determine clinical efficacy.  Each 
supplement was administered daily for four weeks with a two week washout period 
between supplements.  The supplement that produced the most favorable changes was 
supplemented for 30 weeks following the initial study period.  Levels of Krebs cycle 
intermediates, α-ketoglutarate, succinate, and fumarate increased significantly compared 
to baseline during citrate supplementation.  Glutamine levels did not decrease with 
increasing ammonia levels.  Glutamate and alanine levels significantly increased, rather 
than decreased with increasing ammonia levels.  There was a significant direct 
correlation between lysine and ammonia.  Hospitalizations per year decreased 
significantly in the 2 years following the study compared to the 2 years before and 
during the study.  These results indicate that citrate entered the Krebs cycle providing 
successful anaplerotic therapy by increasing levels of the downstream intermediates of 
the Krebs cycle: -ketoglutarate, succinate and fumarate. Citrate supplements appear to 
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Propionic acidemia is an autosomal recessive disorder caused by deficiency of 
propionyl- CoA carboxylase, the enzyme that converts propionyl-CoA to methylmalonyl-
CoA (Figure 1) using the cofactor biotin (1).  This mitochondrial pathway is essential for 
degradation of the amino acids isoleucine, methionine, threonine, and valine, odd chain 
fatty acids, and cholesterol (1).  Propionic acid also originates from the catabolism of the 
nucleotides thymine and uracil and from bacterial production of propionate from 
pyruvate in the gut (1).  Propionyl-CoA is eventually converted into succinyl-CoA and 
enters the citric acid (Krebs) cycle for energy production.  In propionic acidemia, excess 
propionyl-CoA combines with oxaloacetate, an intermediate of the Krebs cycle, to form 
methylcitric acid, the diagnostic metabolite of propionic acidemia.  
Most cases of propionic acidemia present with lethargy progressing to coma from 
16 hours to weeks after birth, depending on the severity of the enzyme impairment 
caused by the genetic lesion (1). Coma is caused by metabolic imbalance and severe 
hyperammonemia that can be associated, or not, with metabolic acidosis (2).  Even when 
patients are rescued from the hyperammonemic coma, the prognosis is poor since patients 
can develop life-threatening complications such as pancreatitis or cardiomyopathy (3, 4). 







Figure 1. Propionyl-CoA and glutamine metabolism in propionic acidemia. 
Propionyl-CoA is carboxylated by propionyl CoA carboxylase to become 
D-methylalonyl-CoA.  With the action of methymalonyl CoA racemase and 
mutase, this produces succinyl-CoA that fills up the Krebs cycle.  In 
propionic acidemia, propionyl-CoA accumulates and condenses with 
oxaloacetate to produce methylcitric acid.  The decrease in oxaloacetate and 
succinyl-CoA can impair the Krebs cycle, reducing the concentration of α-
ketoglutarate. This can be repleted to the expense of glutamine and 
glutamate.  GDH: Glutamate dehydrogenase; MAAT: mitochondrial 






mortality even in optimally treated patients limiting the benefits of early diagnosis by 
newborn screening programs (3, 4).   
Ammonia accumulation in organic acidemias can be secondary to inhibition of 
carbamylphosphate synthase-1 (CPS-1), the first enzyme of the urea cycle.  In fact, 
propionyl-CoA competitively inhibits the synthesis of N-acetylglutamate (5), an allosteric 
activator of CPS-1 whose levels are reduced in livers of rats receiving propionic or 
methylmalonic acid (6), and N-carbamylglutamate, a precursor of N-acetylglutamate, 
reduces plasma ammonia levels in patients with propionic or methylmalonic acidemia (7, 
8).  Chronic hyperammonemia in propionic acidemia, however, differs from that of urea 
cycle defects, since it is not accompanied by an increase in glutamine, the amino acid that 
shuttles nitrogen groups to the liver for ammonia formation and detoxification (9, 2, 10).   
Ammonia is generated from amino acid metabolism within the absorptive cells of 
the intestine, from bacterial hydrolysis of urea in the colon, from catabolism of branched 
chain amino acids in peripheral tissues (muscle) with generation of alanine and 
glutamine, and from the catabolism of all amino acids within the liver.  Most of the 
ammonia arrives to the liver from the portal vein which has an ammonia concentration 
higher than that of the systemic circulation.  In periportal hepatocytes, the urea cycle is 
extremely active.  The ammonia not converted to urea by periportal hepatocytes can be 
conjugated with glutamate to form glutamine by the high-affinity glutamine synthase in 
centrolobular hepatocytes (11).  In urea cycle defects, the excess ammonia reaching 
centrolobular hepatocytes results in extremely elevated glutamine levels.  
In propionic acidemia, glutamine levels are low even in well-controlled patients 





this glutamine paradox, also seen by other groups (9, 2, 10), could be due to a 
dysfunctional Krebs cycle, with deficiency of α-ketoglutarate (12).  In propionic 
acidemia, glutamate dehydrogenase, normally a cataplerotic enzyme favoring the exit of 
α-ketoglutarate as glutamate (13), works in reverse generating α-ketoglutarate from 
glutamate (12).  Low levels of glutamate favor the release of ammonia from glutamine to 
generate glutamate, explaining the association between high ammonia and low glutamine 
levels.   
Propionic acid is important in the anaplerosis (filling-up) of the Krebs cycle as 
indicated by the clinical improvement of patients with fatty acid oxidation disorders and 
pyruvate carboxylase deficiency treated with heptanoin, an odd-chain fatty acid that is 
metabolized to propionic acid and converted to succinyl-CoA (14, 15).  Since such a 
mechanism is so effective in replenishing the Krebs cycle, its complete absence in 
patients with propionic acidemia, coupled with the sequestration of oxaloacetate by 
propionyl-CoA to form methylcitrate, should result in a severe deficiency of all 
intermediates of the citric acid cycle.  In muscle, α-ketoglutarate is the intermediate with 
the lowest concentration (0.05 mmol/kg) after oxaloacetate (0.012 mmol/kg, (13, 16)).  α-
Ketoglutarate concentration further declines with exercise (13) and is regenerated from 
glutamine and glutamate (13, 16).  If glutamine/glutamate and α-ketoglutarate are too 
low, such as in propionic acidemia (12), the process might become ineffective in 
generating energy, possibly contributing to hypotonia and organ failure.  
Supplements can provide substrates to the Krebs cycle.  In patients with 
argininosuccinic aciduria, citrate, the intermediate with the highest concentration in the 





increase conjugation with citrulline and the urinary excretion of the water-soluble 
argininosuccinic acid (18, 19).  This action does not require entry of citrate into 
mitochondria and this therapy is not routinely used given its modest efficacy and possible 
side effects (metabolic alkalosis, (19)).  Citrate in combination with aspartate stabilized 
the metabolic control of one patient with pyruvate carboxylase deficiency (20) and 
increased plasma glutamine levels in another patient (14).  Both patients had severe 
neurological compromise and citrate effects on the overall outcome were difficult to 
assess given the concomitant use of other medications/supplements (14, 20).  
Other natural supplements include glutamate, glutamine, and α-ketoglutarate. 
Glutamate is mostly (>90%) metabolized by the splanchnic bed, while more than 50% of 
oral glutamine can reach the circulation and increase glutamate production (21). 
Glutamine has been used extensively in the treatment of very low birth weight infants in 
whom it is extremely safe (up to 0.6 g/kg/day) and prevents protein catabolism (22). 
Glutamine (2 g/m
2
 BID) decreases narcotic requirements and the number of days of 
intravenous hyperalimentation in cancer patients receiving chemotherapy (23).  α-
Ketoglutarate is available as a salt or in combination with the positively charged amino 
acids arginine and ornithine.  The salt form and arginine α-ketoglutarate are widely 
available as supplements, but only limited clinical trials have been reported (24). 
Ornithine α-ketoglutarate has been used since the early 1960s and is more effective than 
α-ketoglutarate or ornithine alone in increasing glutamine levels in healthy subjects (24). 
This is because ornithine can be converted into glutamate through ornithine amino 
transferase and Δ1pyrroline-5-carboxylate dehydrogenase (Figure 2) (24, 25).  Ornithine 


















receiving total parental nutrition (26, 27).  The combination of ornithine and α-
ketoglutarate can spare endogenous glutamine (increasing its plasma levels), feed directly 
into the Krebs cycle, and participate in the synthesis of urea cycle amino acids (25). 
Since in propionic acidemia there is a direct correlation between plasma levels of 
glutamine/glutamate and levels of the urea cycle amino acids ornithine and arginine (12), 
the simultaneous administration of ornithine and α-ketoglutarate should have a 
synergistic effect.  Both glutamine and ornithine α-ketoglutarate are extremely well 
tolerated in humans at doses up to 0.6 g/kg/day and have not caused any known adverse 
reaction.  They are freely available as nutritional supplements to the general public and 
are marketed mostly as daily supplements for body builders or for general health.   
Figure 2. Selected pathways of ornithine metabolism.  
Ornithine can be converted to glutamate by the action of two enzymes, 






A mouse model of propionic acidemia has been generated by disrupting the gene 
encoding the α subunit of the enzyme (28).  Affected mice die at birth by acute 
ketoacidosis, but can be rescued by gene therapy (28).  In the initial experiments, all 
animals died even with this therapy since it was difficult to obtain the appropriate gene 
dosage to allow survival (28).  More recently, gene therapy with adeno-associated virus 
serotype 8 gene transfer was effective in rescuing the neonatal lethal phenotype of mice 
with propionic acidemia (34).  It remains a formidable task to study in these mice the 
effects not only of a restricted diet, but also of dietary supplements.  
Our hypothesis is that functional insufficiency of the citric acid (Krebs) cycle in 
propionic acidemia decreases production of α-ketoglutarate that is replenished by 
glutamine/glutamate.  Decreased availability of glutamate/glutamine explains the chronic 
hyperammonemia of patients with propionic acidemia while decreased ATP production 
could be responsible for the low muscle tone and progressive organ dysfunction.  To test 
this hypothesis, anaplerotic supplements (citrate, glutamine, or ornithine α-ketoglutarate) 
were administered to patients with propionic acidemia to evaluate their effects on plasma 
levels of glutamine and ammonia, and the urinary excretion of Krebs cycle intermediates 
(to determine whether the supplements entered mitochondria).  In addition, the clinical 
efficacy of these supplements was tested by looking at mental and physical development 
and hospital admissions.  This therapy would be relatively easy for these patients 
(supplements can be added to their special formula), inexpensive, and could potentially 
lead to great benefit by preventing one of the major causes (hyperammonemia) of mental 
deterioration and death.  More importantly, a dysfunction of the Krebs cycle with 





(hypotonia, organ failure) of patients even with mild variants of propionic acidemia.  This 
therapy, if effective in the small number of patients tested in this project, could be 
extended to patients with other organic acidemias (methylmalonic acidemia and possibly 
others) with a larger, multicenter clinical trial, required to enroll a sufficient number of 










  Three patients with propionic acidemia followed at the University of Utah since 
birth were enrolled in this study.  Their ages at time of enrollment ranged from 5.9 to 11 
years of age. Their developmental quotient/IQ ranged from moderately to severely 
delayed with the gross motor area being the most affected.  Each patient in the 2 years 
prior to the trial required two to six hospital admissions per year to control metabolic 
decompensation or intercurrent illnesses.  Their metabolic control was typically excellent.   
 Prior to beginning and at the conclusion of the study, each patient received a 
cognitive and motor evaluation.  The cognitive evaluation was completed by a licensed 
psychologist (Dr. Nancy Cantor) using the Stanford-Binet Intelligence Scales (SB5), 
Fifth Edition.  The motor activity assessment was performed by a licensed physical 
therapist (Dr. Eduard Gappmaier) and included hand-held myometry studies, time-
function tests, and an accelerometry evaluation.   
 The study occurred in two parts.  In the first part, individual supplements 
(ornithine α-ketoglutarate, glutamine, and citrate) were evaluated for their ability to raise 
plasma glutamine levels, or to cause other biochemical changes as compared to baseline 
(before the study and during wash-out periods).  In the second part, the diet of the 
patients was supplemented with the supplement judged to produce the most favorable 
changes (citrate) for 30 weeks.  Doses of supplements (ornithine α-ketoglutarate, 





were not changed during the corresponding treatment period (4 weeks or 30 weeks).  
Ornithine α-ketoglutarate 400 mg/kg (2 mmol/kg ornithine, 1 mmol/kg α-ketoglutarate) 
per day was started at week 0 and continued until week 4.  Week 4-6 was a washout 
period with no supplements for 2 weeks.  Glutamine 400 mg/kg (2.74 mmol/kg) per day 
was started at week 6 and continued through week 10.  A second washout period 
occurred from week 10-12 with no supplements for 2 weeks.  At week 12, citrate (7.5 
mEq/kg, 2.5 mmol/kg) was started and continued through week 16.  The final washout 
period occurred from week 14-16.  At week 18, citrate was started at the same dosing 
level and continued through week 48 when measurements were repeated, the study was 
officially concluded, and patients were offered to continue citrate supplements on a 
clinical basis.  All patients continued citrate supplements for at least 2 years following the 
conclusion of the study.  
  Study visits occurred each week starting at baseline and continued until week 16, 
with the exception of two week washout periods.  During the final treatment period, week 
18-48, study visits occurred every 6 weeks.  Each study visit included a physical exam 
along with anthropometric and vital sign measurements.  Diet records were collected and 
analyzed during the final visit of each trial period (weeks 4, 10, 16, 48).  Concomitant 
medications and therapies were collected and recorded.   
After the initial evaluation, parents were given the nutritional supplement to mix 
in the child’s metabolic formula containing all amino acids except propiogenic amino 
acids (isoleucine, methionine, threonine and valine).  Patients were also receiving a 
measured amount of natural proteins from regular food.  Following the initial study 





term alterations in amino acid levels and plasma ammonia levels.  Data were collected 
through a retrospective chart review. 
Study labs included plasma amino acids, acylcarnitine profile, ammonia, lactic 
acid, and urine organic acids.  Biochemical tests were performed at ARUP laboratories of 
the University of Utah.  Plasma amino acids were analyzed by ion-exchange 
chromatography with post-column ninhydrin detection (Biochrom 30 amino acid 
analyzer) (29).  Urinary organic acids were analyzed by gas chromatography-mass 
spectrometry (HP/Agilent) (30).  Plasma acylcarnitine levels and profile were determined 
by tandem mass spectrometry (Waters Quattro Premiere) using stable isotope standards 
for quantitation. Dr. Marzia Pasquali (ARUP) quantified analytes not routinely reported 
(methylcitrate, other propionic acid metabolites in urine, propionylcarnitine in plasma), 
performed subsequent data analysis, and oversaw consistency of measurements among 
different samples.   
  Plasma amino acids were compared before and after treatment with anaplerotic 
agents. Baseline study labs (week 0, 6, 12, and 18) (ammonia, amino acids, organic acids, 
lactic acid) were averaged and compared to those obtained during treatment with 
ornithine α-ketoglutarate (n=4), glutamine (n=4) and citrate (n=4).  Data were compared 
using analysis of variance with p<0.05 as a statistical cutoff. Patients were initially tested 
against themselves and subsequently data were pooled together to determine if any 
significant differences occurred.  Correlation analysis was also used to compare plasma 
ammonia levels to glutamine levels.  Calculations were performed using Microsoft Excel 










Patients and Safety 
 
  Table 1 summarizes the clinical and anthropometric data of patients with 
propionic acidemia.  Three patients participated in this study (age at the beginning of the 
study ranged from 5.9 to 11 years).  Anthropometric measures (weight, height, head 
circumference, and BMI) varied by patient.  There were no significant changes in 
measurement values or percentiles from the beginning to the end of the study.  BMI 
improved in all 3 patients during the study, with percentiles that increased in two patients 
who were underweight at the beginning of the study (from the 22
nd
 to the 50
th
 and from 
the 3
rd
 to the 46
th
 percentile, respectively) and decreased in a third patient who was 
overweight (from the 95
th
 to the 91
st 
percentile), though these improvements were not 
statistically significant.    
  Table 2 reports levels of hemoglobin, white blood cell counts, platelets, 
transaminases, alkaline phosphatase, total proteins and albumin at baseline and during 
treatment with ornithine α-ketoglutarate, glutamine or citrate.  There were no statistically 
significant differences between average biochemical baseline values and averages from 
each of the three treatment periods for the lab values reported (Table 2).  Patients also 
had normal free thyroxine and thyroid stimulating hormone when measured at baseline 








Demographic information in patients with propionic acidemia.  Measurements taken at baseline and at the conclusion of the study 
period.  Results reported as mean ± SD. 
 
 
 Patient 1 2 3 
Average: 
 Gender F F M 
 Race Hispanic  White White 
Age (yr) Before 5.9 11 6.8 7.9 ±2.7 
After 7.3 12.2 7.8 9.1±2.7 
Weight, kg (centile) Before 15.6 (2) 45.2 (80) 20.2 (18) 27±15.9 (33±41) 
After 19.7 (9) 48.9 (74) 27.2 (67) 31.9±15.2 (50±36) 
Height, cm (centile) Before 104.5 (2) 136.5 (14) 122 (57) 120.5±22.6 (24±29) 
After 112.5 (1) 143.3 (10) 132 (80) 127.9±21.8 (30±43) 
Head circumference, 
cm (centile) 
Before 47.2 (<3) 51 (10) 49.5 (3) 49.2 ± 1.9 
After 48 (<3) 51.5 (10) 50 (3) 49.8±1.8 
Body mass Index, 
kg/m
2
  (centile) 
Before  14.3 (22) 24.3 (95) 13.6 (3) 17.4 ± 6 (40±48.6) 















Safety Labs in patients with propionic acidemia. Values are averages ± SD of at least 12 observations. OKG: Ornithine α-
ketoglutarate. 
Labs: Normal Baseline Citrate Glutamine OKG 
Hemoglobin (g/dL) 11-13.3 13.1± 2.1 12.8±1.4 12.6±1.1 12.1±1.0 
White Blood Cells (k/uL) 4.5-10.5 5.3±1.5 5.2±1.8 6.0±2.5 5.4±1.0 
Platelets (k/uL) 204-405 234±70 233±70 273±90 302±94 
AST (U/L) 20-60 60.3±24.4 59.9±22.4 47.9±11.4 44.9±6.7 
ALT (U/L) 5-45 45.8±29.6 54.2±32.4 33.5±15.7 35.4±11.5 
Alk. Phos (U/L) 145-320 189±57 207±44 191±53 175±51 
Total Protein (g/dL) 5.9-7.0 6.7±0.7 6.6±0.5 6.9±0.6 6.7±0.7 








study.  Serum lactate levels also did not change significantly during the study, with very 
few values above the normal range.  As noted in Figure 3A, ammonia levels did not 
change significantly during the trial as did the urinary excretion of lactate and pyruvate 
(Figure 3B).  Overall, routine lab values were not significantly affected by any of the 
treatments indicating overall safety of the supplements. 
 
Amino Acids and Organic Acids 
 
  In the first part of the study, patients with propionic acidemia received three 
different supplements (ornithine α-ketoglutarate, glutamine and citrate) for 4 weeks with 
blood testing every week.  Values obtained in the presence of supplements were 
compared to baseline (before the initiation of the study and during wash-out periods).  
None of the treatments significantly increased [glutamine] or [glutamine] + [glutamate] 
concentration nor significantly decreased plasma ammonia (Figure 3A).  For this reason, 
we looked at the urinary excretion of Krebs cycle intermediates (urine organic acids) for 
evidence that the supplements entered mitochondria.  Levels of ketoglutarate did not 
increase significantly during treatment with ornithine α-ketoglutarate or glutamine, but 
did increase significantly during citrate therapy (p<0.01) (Figure 3B).  Levels of fumarate 
and succinate also increased significantly during citrate treatment compared to baseline 
(p<0.001), but not with the two other supplements.  Levels of lactate, pyruvate, and 
citrate also increased during citrate treatment, though this increase was not statistically 
significant compared to baseline.  In summary, citrate, but not glutamine nor ornithine α-
ketoglutarate significantly increased the urinary excretion of ketoglutarate, succinate and 





modification by enzymes of the Krebs cycle (Figure 3B, 3C).  At the same time, there 
was no statistically significant increase in the excretion of lactate and pyruvate, which 
accumulate when the Krebs cycle is dysfunctional.  Thus, citrate was supplemented in the 
second part of the study for 30 weeks.  
  To evaluate changes in plasma amino acids, the results of both parts of the study 
were grouped together and are summarized in Tables 3 and 4 and Figure 3.  Table 3 
shows the average values of the 22 amino acids collected at baseline and during each 
treatment period.  The majority of amino acids remained unchanged throughout the study.  
As expected, ornithine levels increased significantly (p<0.001 compared to baseline) 
during ornithine α-ketoglutarate supplementation.  This indicated that the chemical was 
successfully absorbed in the gut.  However, ketoglutarate excretion in urine did not 
increase during the ornithine α-ketoglutarate treatment period (Figure 3B) indicating that 
α-ketoglutarate was either metabolized prior to entry into mitochondria or did not enter 
the Krebs cycle in sufficient amounts to increase its urinary excretion or that of 
downstream metabolites.   
  Leucine, phenylalanine and threonine decreased significantly compared to 
baseline (Table 3) during supplementation with ornithine α-ketoglutarate (p<0.01, 
p=0.014, and p=0.037, respectively), possibly due to increased restriction of natural 
proteins and use of formula not containing threonine.  The only amino acid that changed 
significantly (p=0.02) during citrate supplementation was leucine that decreased about 
15% below baseline (Table 3).  This might have also been due to mildly increased dietary 
restriction of natural proteins.  








Figure 3. Effect of anaplerotic therapy on selected plasma amino acids, ammonia, and 
urine organic acids.   Effect of anaplerotic therapy on (A) select amino acids, ammonia 
and  (B) urinary organic acids in patients with propionic acidemia. Each value is the 
average ± SD of at least 12 observations. (C) Schematic of the Krebs cycle.   





Amino Acid Normal Baseline Citrate Glutamine OKG 
Alanine 240-600 349.1 ± 84.5 330.9 ± 91.2 328 ± 79 362.3 ± 64.8 
Arginine 40-160 42.8 ± 11.7 36.5 ± 10.2 45.3 ± 21.4 41.4 ± 10.9 
Asparagine 15-40 31.2 ± 13.1 27.6 ± 9.9 26 ± 9.5 29.2 ± 5.0 
Aspartate 0-20 11.1 ± 4.6 9.9 ± 2.8 9.7 ± 2.5 11.7 ± 2.8 
Citrulline 10-60 19.58 ± 4.21 17.5 ± 4.9 21.4 ± 7.9 21.9 ± 4.8 
Cysteine 7-70 34 ± 7.5 29.7 ± 6.9 33.5 ± 7.1 32.1 ± 7 
Glutamine 410-700 365.3 ± 54.5 374.7 ± 49.1 367.3 ± 55.3 390.9 ± 73.7 
Glutamate 10-120 51.2 ± 14.2 50.7 ± 15.6 49.7 ± 12.6 52 ± 7.3 
Glycine 140-490 1268.3 ± 176.6 1173 ± 244 1248.8 ± 229.1 1376.1 ± 157.9 
Histidine 50-130 76.9 ± 20.3 67.7 ± 22.1 60.8 ± 20.2 71.9 ± 20.4 
Isoleucine 30-130 20.7 ± 10.6 20.6 ± 9.5 20.7 ± 11 23.3 ± 9.5 
Leucine 60-230 69.5 ± 35.7 60.8 ± 21.7* 64.3 ± 22.6 50.1 ± 15.8 
Lysine 80-250 227.3 ± 76.1 225.8 ± 68.3 243.9 ± 102.8 224.3 ± 82.2 
Methionine 17-53 12.6 ± 3 13.5 ± 3.6 13.9 ± 3.9 12.7 ± 2.9 
Ornithine 20-135 40.7 ± 16.9 32.6 ± 16 37.3 ± 12.7 94.3 ± 39.2* 
Phenylalanine 30-80 42.6 ± 9.5 41 ± 7 39.4 ± 7.9 34.3 ± 5.2* 
Proline 110-500 252.0 ± 92 307.8 ± 78.5 264.1 ± 64.3 283.8 ± 70.2 
Serine 60-200 142.4 ± 21.7 131.7 ± 28.5 131.7 ± 32.7 147 ± 17 
Taurine 25-80 67.8 ± 15.6 60.8 ± 8.8 61.2 ± 7.1 66.5 ± 10.2 
Threonine 60-220 65.3 ± 15.2 74 ± 26 55.4 ± 14.2 54.1 ± 8.7* 
Tyrosine 30-120 79.8 ± 20.8 67.4 ± 20 80.1 ± 21 66.1 ± 17.6 




Plasma Amino Acids 
Plasma Amino Acids (mol/L) in patients with propionic acidemia. Values are averages ± SD of at least 12 observations. 













 Significance P 
Alanine 0.07* 0.041 
Arginine 0.29* <0.001 
Asparagine 0.01 0.380 
Citrulline 0.13* 0.006 
Cysteine 0.01 0.388 
Glutamine 0.02 0.282 
Glutamine + Glutamate 0.05 0.112 
Glutamine + Glutamate + Alanine 0.09* 0.026 
Glutamate 0.12* 0.008 
Glycine 0.06 0.074 
Histidine  0.02 0.240 
Isoleucine 0.01 0.369 
Leucine 0.11* 0.012 
Lysine 0.52* <0.001 
Methionine 0.02 0.278 
Ornithine 0.05 0.108 
Phenylalanine 0.10* 0.014 
Proline 0.006 0.582 
Serine 0.02 0.246 
Threonine 0.04 0.148 
Tyrosine 0.13* 0.007 
Valine 0.005 0.608 
Correlation of ammonia levels with plasma amino acids in patients with 
propionic acidemia during the clinical trial.  Statistical significance was 
calculated using analysis of variance. R2 and p are indicated.  






  In propionic acidemia, glutamine levels are low even in well-controlled patients 
and decrease (rather than increase) with hyperammonemia (12).  This might be due to 
low levels of α -ketoglutarate favoring release of nitrogen from glutamine and glutamate 
to generate the Krebs cycle intermediate (12).  Since all supplements used in the study 
could have potentially increased α -ketoglutarate and reversed this relationship, we 
explored whether the negative correlation between ammonia and glutamine/glutamate 
and alanine were still observed during the study.  As shown in Figure 4 and Table 4, 
glutamine levels did not decrease with increasing ammonia levels (panel B) and levels of 
glutamate (A) and alanine (C) significantly increased, rather than decreased with 
increasing ammonia levels.  This suggests that these therapies might have re-established, 
at least in part, ketoglutarate levels and the physiological mechanism of ammonia 
buffering by the centrilobular hepatocytes.  
  In propionic acidemia, levels of ammonia positively correlated with an increase in 
the amino acids leucine, tyrosine and phenylalanine (12).  During this clinical trial we 
observed the same trend (Table 4, Figure 5C, E, F).  Since these amino acids are essential 
and provided both by natural proteins and the special formula that patients with propionic 
acidemia consume, these results suggest that ammonia levels correlated to overall protein 
intake.  In addition to these large neutral amino acids, arginine, citrulline, and lysine 
increased with ammonia levels (Figure 5A, B, D), with lysine rising in many occasions 
above the normal range (Figure 5D).  There was no significant correlation between 






Figure 4. Correlation of ammonia levels with selected plasma amino acids.  
Correlation of ammonia levels with select plasma amino acids in patients 
with propionic acidemia during the clinical trial. Data were analyzed by 
linear regression Results for each amino acid are indicated in the figure. 

















































A Glutamate B Glutamine





Figure 5.  Correlation of ammonia levels with selected plasma amino acids. 
Correlation of ammonia levels with selected plasma amino acids in patients with 
propionic acidemia during the clinical trial. Data were analyzed by linear regression 
Results for each amino acid are indicated in the figure.  The shaded area represents the 










































































Cognitive and Motor Assessment 
  The cognitive assessment (Table 5) indicated that all patients had severely 
compromised intellectual abilities before the study.  There were no changes in nonverbal 
IQ, verbal IQ, or full scale IQ from the beginning to the end of the study in patients 1 or 
2.  Patient 3 was too severely affected and unable to complete the evaluation at the 
beginning and end of the study.   
  Table 6 shows the results from the motor assessment of patients 1 and 2.  Patient 
3 was unable to perform the tasks of the assessment.  The hand-held myometry composite 
score increased for both patient 1 and 2 during the course of the study.  Results of the 
time function tests were variable between the patients.  Time required to walk/run 10 
meters and to climb 4 stairs improved for patient 1, but the time to rise from supine to 
stand worsened.  Patient 2 was unable to complete the 10 meter walk/run and the rise 
from supine to stand test because she did not have her walker during the final day of 
testing.  The time to climb four stairs worsened for patient 2 during the study.  
Accelerometry studies showed that both patient 1 and 2 became less active from the 
beginning to the end of the study with decreases in average steps in 7 days, average 




  To evaluate the effect of treatment on overall health, we counted the number of 
days that our patients spent in the hospital before, during and after the clinical trial while 
they were continuing on the supplements (Table 7). Hospitalization days were normalized 





















1 42 (<0.1) 42 (<0.1) 43 (<0.1) 43 (<0.1) 40 (<0.1) 40 (<0.1) 
2 42 (<0.1) 42 (<0.1) 43 (<0.1) 43 (<0.1) 40 (<0.1) 40 (<0.1) 
3 Child not sufficiently cooperative 
Average:  42 (<0.1) 42 (<0.1) 43 (<0.1) 43 (<0.1) 40 (<0.1) 40 (<0.1) 











  Pt: 1 2 
Hand-Held Myometry Composite Score (lbs) Before 10.85 12.6 
After 14.7 12.85 
Time Function Test 10 meter walk/run (sec) Before 7.1 14.6 
After 5 NA** 
Time to rise from supine to 
stand (sec) 
Before 3.3 NA** 
After 4.2 NA** 
Time to climb 4 stairs (sec) Before 4.3 12.9 
After 2.7 14.7 
Accelerometry Tests Average steps in 7 days Before 7679 2192 
After 5599 1891 
Average minutes of activity 
in 7 days 
Before 496 247 
After 485 227 
Average % of inactivity in 7 
days 
Before 65.5 82.8 
After 66.3 84.21 
Evaluation of muscle activity in patients with propionic acidemia. Results reported at baseline and at the conclusion of 
the study. 
*Patient 3 was unable to complete the evaluation of muscle activity. 











 Two years prior to study During study Two years following study 
Pt: Days Hospitalized ER visits Days Hospitalized ER visits Days Hospitalized ER visits  
1 19 3.5 10 2.1 4.5 0.5 
2 25 0.5 32 0 0 0.5 
3 2 0 5.5 0 1 0 
Average± SD 15.3±11.9 1.3±1.9 15.8±14.2 0.7±1.2 1.8±2.4* 0.3±0.3 
Total: 46 4 47.5 2.1 5.5 1 
Hospitalizations in patients with propionic acidemia before, during and after anaplerotic therapy.  Average number of days 
hospitalized and ER visits in patients with propionic acidemia two years prior to study, during study, and two years following 
study. The number of days spent in the hospital was normalized per year.  









before and after the study.  The cause of hospitalizations was related mostly to respiratory 
problems, pancreatitis, or viral infections.  In no case were adverse events deemed related 
to treatment, but rather to the underlying medical condition or intercurrent illnesses. 
Patients with propionic acidemia did not have any change in the number of days in the 
hospital during the study.  However, the average number of days/year that patients were 
hospitalized significantly decreased during the 2 years after the study, while the patients 
continued to supplement with open-label citrate, as compared to the 2 years prior to the 
study (p=0.04) or during the study (p=0.03).  This suggests that citrate therapy might be 
clinically effective, but might require prolonged time before generating measurable 
changes.  The number of ER visits not leading to hospital admissions during and after the 
study was also lower than the number of ER visits per year during the 2 years prior to the 












  The objective of this study was to determine whether citrate, glutamine, or 
ornithine α-ketoglutarate were effective in raising plasma glutamine and reducing plasma 
ammonia levels compared to baseline in patients with propionic acidemia.  All 
supplements were safe, with no adverse events attributed to them nor changes in safety 
laboratory values (Table 2).  Growth remained appropriate during the study.  BMI 
(kg/m
2
) increased in patients 1 and 3, who started with a BMI lower than average, and 
decreased in patient 2, who started with an above average BMI (Table 1).  Overall, there 
were no indications that any of the supplements were detrimental to the patients’ health.   
  In the first part of the study, none of the supplements significantly raised the 
plasma glutamine or [glutamine+glutamate] concentration (Figure 3A).  Ammonia levels 
also did not change significantly during therapy with any of the 3 supplements.  Despite 
lack of significant changes in glutamine levels, urine organic acids indicated that 
treatment with citrate, but not the other supplements, significantly increased the excretion 
of ketoglutarate, succinate and fumarate (Krebs cycle intermediates, Figure 3B, C), 
indicating that citrate entered mitochondria and was converted to  subsequent 
intermediates in  the Krebs cycle possibly providing successful anaplerotic therapy.  For 
this reason, treatment with citrate was continued over time (30 weeks) to determine its 





  Even with a longer period of time on citrate, therapy failed to significantly 
increase glutamate or glutamine levels (Table 3).  The only changes that were observed in 
the plasma amino acids were an increase in ornithine in patients receiving ornithine α-
ketoglutarate and a reduction in some essential amino acids, possibly reflecting more 
strict dietary compliance.  With respect to plasma ammonia, the inverse relationship 
between plasma ammonia and glutamine levels (12) was lost during the trial (Figure 4), 
suggesting that more substrate (ketoglutarate) may have been available to hepatocytes to 
conjugate ammonia escaping the urea cycle in periportal hepatocytes.  At the same time, 
there was a striking direct correlation between ammonia and lysine levels (R
2
=0.52, 
p<0.0001) (Figure 5).  Lysine levels increase in many forms of hyperammonemia and in 
urea cycle defects.  Since lysine is an essential amino acid, its increased levels likely 
reflect decreased degradation.  There are two pathways devoted to lysine breakdown: the 
saccharopine and the pipecolic acid routes that ultimately converge at the level of al α-
aminoadipic semialdehyde.  In the saccharopine pathway, that is believed to be the main 
catabolic route, L-lysine is converted to saccharopine by α-aminoadipic semialdehyde 
synthase by condensation with α-ketoglutaric acid (35, Figure 6).  In the pipecolic acid 
pathway, transamination also requires an acceptor for ammonia that, in most cases, is α -
ketoglutarate.  In urea cycle defects, ammonia combines with α-ketoglutarate to generate 
glutamate and then glutamine, leading to α-ketoglutarate depletion and a secondary 
increase in lysine levels.  In propionic acidemia, it would be the primary depletion of α-
ketoglutarate that results in a stable increase in lysine levels, which further increase when 
residual α-ketoglutarate is conjugated with ammonia to generate glutamic acid.  If this is 














Figure 6. Schematic of lysine degradation pathways.  





successful therapy in  patients with propionic acidemia.  In addition, mild restriction of 
dietary lysine could spare ketoglutarate for anaplerotic functions.  
   Most patients with propionic acidemia have developmental delays.  We tested the 
effects of supplements on cognitive and motor delays.  Only two patients were able to 
participate in the motor assessment, since the third one was too impaired to perform the 
required tasks.  The small sample size precluded any statistical analysis. Cognitive 
function, assessed with the Stanford Binet method, was severely impaired in our patients 
with propionic acidemia (average IQ=40) and did not improve with treatment (Table 5). 
This was not unexpected since all of our patients had a severe initial presentation that 
caused brain suffering not usually responsive to therapy. 
  Hand-held myometry, a test of muscle strength, increased in both tested 
patients from the beginning to the end of the study (Table 6).  No consistent changes 
were measured in time function tests (time required to walk/run 10 meters, to rise from 
supine to stand, and to climb four stairs) and in the accelerometry tests.  The latter test 
showed a decline in activity in both patients from the beginning to the end of the study.  
There are several factors that may have influenced the activity level of patients at the 
beginning and end of the study.  The decrease in activity may be due to differences in 
season/circumstances, from the beginning to the end of the study, rather than a decreased 
ability to be physically active.  These patients also had motor delays prior to beginning 
the study and, overall, were less able to understand and complete the motor evaluation 
tests successfully compared to the general population.  Overall, treatment with citrate did 
not affect cognitive function and was, at best, moderately effective in only one test of 































  While there was no effect on cognitive or motor development, the overall health 
of patients with propionic acidemia might have benefitted from citrate supplementation.  
In the 2 years prior to the study, patients were hospitalized 15.3 days per year on average 
(Table 7).  During the study, the number remained at 15.8 days per year.  In the 2 years 
poststudy, all three patients remained on open label citrate supplements and the average 
number of days hospitalized per year decreased significantly to 1.8 (p=0.04 as compared 
to baseline).  The significant reduction in the number of hospitalization days during this 
time suggests that citrate supplements might improve the general health of patients with 
propionic acidemia, but that the effects of supplements might require time to become 
evident.  The decreased number of hospitalizations could be due to factors other than 
therapy.  In general, patients with propionic acidemia become more clinically stable as 
they get older.  However, the patient who improved the most (patient 2) in this case was 
the oldest of the group and was already 11 years old when the study started.  All of the 
patients improved regardless of age.  Patients and their families also had extended 
contacts with the healthcare team consisting of physicians and dietitians, during the 
study.  Improved education about the disease and consistent monitoring could have 
helped the management of propionic acidemia in the long term.  
   There are several limitations in our study.  Our study involved only three patients 
with propionic acidemia, a rare metabolic disorder, affecting approximately 1:50,000 
worldwide (36).  The results of this pilot study results should be extended to a larger 
population of patients with a multicenter trial enabling enrollment of an adequate number 





  Another factor that may have affected the results of the study may be the dose of 
the supplement.  On a molar basis, OKG dosing provided 2 mmol/kg ornithine, 1 
mmol/kg α-ketoglutarate, glutamine was supplemented at 2.7 mmol/kg, and citrate was 
supplemented at 2.5 mmol/kg.  Therefore, considering that ornithine can be converted 
into ketoglutarate (Figure 2), the dosage of the supplements was almost equivalent.  
However, these dosing levels may have not been high enough to cause glutamine levels 
to rise.  Specifically, the dose of citrate might have increased intermediates of the citric 
acid cycle, but might have not been sufficiently high to increase glutamate and glutamine 










  Propionic acidemia is a rare metabolic disorder caused by deficiency of 
propionyl-CoA carboxylase.  Patients with propionic acidemia generally have a poor 
prognosis due to health complications including pancreatitis or cardiomyopathy.  
Deficient breakdown of propionyl-CoA may lead to deficient levels of Krebs cycle 
intermediates and decreased glutamine levels.  Current treatment in patients with 
propionic acidemia includes a low protein diet with an artificial formula that does not 
contain the amino acids threonine, valine, leucine, and methionine.  Patients receive 
carnitine supplements to replace propionylcarnitine that is lost in urine.  Adding a 
supplement to their treatment regimen would be a simple, effective way to improve the 
prognosis.   
  By supplementing citrate in patients with propionic acidemia, we have shown 
their ability to increase Krebs cycle intermediates through anaplerosis and (for all 
supplements) to normalize the relationship between ammonia and glutamate levels. This 
treatment appears to be safe and effective in the long term in reducing hospitalizations in 
patients with propionic acidemia.  Further testing of citrate therapy at a higher dose on a 
larger population might prove useful not only in treating patients with propionic 
acidemia, but also patients with other organic acidemias in which there is depletion of 
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